Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy

December 20, 2013

An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.

In this issue of the Journal of Clinical Investigation, Frédéric Batteux and colleagues at the Laboratoire d'Immunologie evaluated use of the MRI contrast agent mangafodipir, which has antioxidant properties, for relief of oxaliplatin-associated neuropathies. In a mouse model of oxaliplatin-induced neurologic damage, administration of mangafodipir reduced neurotoxicity and the presence of oxidized protein products. Furthermore, in a cohort of 22 patients with oxaliplatin-associated neuropathy, mangafodipir treatment appeared to decrease neurological symptoms.

In their accompanying commentary, Charles Loprinzi and colleagues at the May Clinic caution that even though these results seem promising, larger clinical trails have not been able to confirm similar results from other agents that have shown promise for treating chemotherapy-induced neuropathy in animal models and small phase II small.
-end-
TITLE: Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

AUTHOR CONTACT: Frederic Batteux
Faculté de médecine, Université Paris-Descartes, Sorbonne Paris-Cité, Paris, , FRA
Phone: 00 33 1 58 41 20 07; Fax: 00 33 1 58 41 20 08; E-mail: frederic.batteux@cch.aphp.fr

View this article at: http://www.jci.org/articles/view/68730?key=6064e89c86534c430e19

ACCOMPANYING COMMENTARY

TITLE: The search for treatments to reduce chemotherapy-induced peripheral neuropathy

AUTHOR CONTACT: Charles Loprinzi
Mayo Clinic, Rochester, , USA
Phone: 507-284-4849; Fax: 507-284-1803; E-mail: cloprinzi@mayo.edu

View this article at:http://www.jci.org/articles/view/73908?key=e458bafc63766b2f6665

JCI Journals

Related Neuropathy Articles from Brightsurf:

Identified the cellular process by which Cisplatin chemotherapy causes neuronal damage
Cisplatin induces senescence of peripheral neurons through overexpression of the p21 protein, which would explain the neuropathy.

Penn researchers identify new genetic cause of a form of inherited neuropathy
Inherited mutations in a gene that keeps nerve cells intact was shown, for the first time, to be a driver of a neuropathy known as Charcot-Marie-Tooth disease.

NUS researchers identify novel protein to prevent neuropathy from chemotherapy
A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy, a major side effect of chemotherapy, in cancer patients.

Poor diet can lead to blindness
An extreme case of 'fussy' or 'picky' eating caused a young patient's blindness, according to a new case report published today [2 Sep 2019] in Annals of Internal Medicine.

Genetic marker linked to increased risk of diabetic peripheral neuropathy
This is the first real effort to have a genome wide search for genes predisposing to diabetic peripheral neuropathy.

Healthy fats improve nerve function in obese mice
Swapping dietary saturated fats for monounsaturated fats reverses nerve damage and restores nerve function in male mice, finds new preclinical research published in JNeurosci.

Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer
A new study assesses chemotherapy-induced peripheral neuropathy in 121 long-term survivors of childhood cancer to detail clinical, functional, neurophysiological and patient-reported outcomes of the condition.

Diagnosing, treating neuropathy symptoms in cancer patients not exact science
Most of the roughly 15.5 million cancer survivors in the US receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.

MDI Biological Laboratory discovery could lead to new therapies for diabetics
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy also plays a role in peripheral neuropathy caused by diabetes.

Researchers test first drug to prevent the onset of chemotherapy-induced neuropathy
Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment.

Read More: Neuropathy News and Neuropathy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.